Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Punjani N, Flannigan R, Kang C, Khani F. Quantifying Heterogeneity of Testicular Histopathology in Men with Nonobstructive Azoospermia. J Urol. 2021;206(5):1268-1275.

Satlin MJ, Chen L, Douglass C, Hovan M, Davidson E, Soave R, et al. Colonization With Fluoroquinolone-Resistant Enterobacterales Decreases the Effectiveness of Fluoroquinolone Prophylaxis in Hematopoietic Cell Transplant Recipients. Clin Infect Dis. 2021;73(7):1257-1265.

Racine-Brzostek SE, Yee JK, Sukhu A, Qiu Y, Rand S, Barone PD, et al. More rapid, robust and sustainable antibody responses to mRNA COVID-19 vaccine in convalescent COVID-19 individuals. JCI Insight. 2021.

Orr CE, Beneck D, Jessurun J, Qin L, Tyryshkin K, Yantiss RK, et al. High interobserver variability and frequent overdiagnosis of dysplasia in fundic gland polyps can be improved by detecting atypia on the surface epithelium and an abrupt transition to non-neoplastic cells. Histopathology. 2021.

Napoli S, Cascione L, Rinaldi A, Spriano F, Guidetti F, Zhang F, et al. Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B cell lymphoma. Haematologica. 2021.

Jessurun J. Helicobacter pylori: an evolutionary perspective. Histopathology. 2021;78(1):39-47.

Panza E, Vellecco V, Iannotti FA, Paris D, Manzo OL, Smimmo M, et al. Duchenne's muscular dystrophy involves a defective transsulfuration pathway activity. Redox Biol. 2021;45:102040.

Choi JJ, Westblade LF, Gottesdiener LS, Liang K, Li HA, Wehmeyer GT, et al. Impact of a Multiplex Polymerase Chain Reaction Panel on Duration of Empiric Antibiotic Therapy in Suspected Bacterial Meningitis. Open Forum Infect Dis. 2021;8(10):ofab467.

Hu Q, Poulose N, Girmay S, Helevä A, Doultsinos D, Gondane A, et al. Inhibition of CDK9 activity compromises global splicing in prostate cancer cells. RNA Biol. 2021:1-8.

Cho C, Hilden P, Avecilla ST, Barker JN, Castro-Malaspina H, Giralt SA, et al. Combining the Disease Risk Index and Hematopoietic Cell Transplant Co-Morbidity Index provides a comprehensive prognostic model for CD34+-selected allogeneic transplantation. Adv Cell Gene Ther. 2021;4(1).